230 related articles for article (PubMed ID: 24852041)
1. Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.
Brito AF; Mendes M; Abrantes AM; Tralhão JG; Botelho MF
Mol Diagn Ther; 2014 Oct; 18(5):495-504. PubMed ID: 24852041
[TBL] [Abstract][Full Text] [Related]
2. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in rat models with hepatocellular carcinoma with liver cirrhosis.
Park SI; Lee JH; Ham HJ; Jung YJ; Park MS; Lee J; Maeng LS; Chung YA; Jang KS
Biomed Mater Eng; 2015; 26 Suppl 1():S1669-76. PubMed ID: 26405933
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of technetium-99m tetrofosmin liver imaging to detect hepatocellular carcinoma and related to expression of P-glycoprotein or multidrug resistance associated protein-a preliminary report.
Ding HJ; Huang WT; Tsai CS; Chang CS; Kao A
Nucl Med Biol; 2003 Jul; 30(5):471-5. PubMed ID: 12831984
[TBL] [Abstract][Full Text] [Related]
5. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
Lee M; Ko H; Yun M
Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
[TBL] [Abstract][Full Text] [Related]
7. PET Imaging of Hepatocellular Carcinomas:
Zhao J; Zhang Z; Nie D; Ma H; Yuan G; Su S; Liu S; Liu S; Tang G
Mol Imaging; 2019; 18():1536012118821032. PubMed ID: 30799682
[TBL] [Abstract][Full Text] [Related]
8. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of
Lee SM; Kim HS; Lee S; Lee JW
World J Gastroenterol; 2019 Mar; 25(11):1289-1306. PubMed ID: 30918424
[TBL] [Abstract][Full Text] [Related]
10. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
11. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
Paudyal B; Paudyal P; Oriuchi N; Tsushima Y; Nakajima T; Endo K
Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of
Ida Y; Tamai H; Shingaki N; Shimizu R; Maeshima S; Maekita T; Iguchi M; Terada M; Kitano M
Cancer Imaging; 2020 Oct; 20(1):74. PubMed ID: 33076990
[TBL] [Abstract][Full Text] [Related]
13. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.
Asman Y; Evenson AR; Even-Sapir E; Shibolet O
Liver Transpl; 2015 May; 21(5):572-80. PubMed ID: 25644857
[TBL] [Abstract][Full Text] [Related]
14. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor.
Tsurusaki M; Okada M; Kuroda H; Matsuki M; Ishii K; Murakami T
J Gastroenterol; 2014 Jan; 49(1):46-56. PubMed ID: 23525980
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer.
Higashi K; Ueda Y; Ikeda R; Kodama Y; Guo J; Matsunari I; Oguchi M; Tonami H; Katsuda S; Yamamoto I
Nucl Med Commun; 2004 Jan; 25(1):19-27. PubMed ID: 15061261
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
[TBL] [Abstract][Full Text] [Related]
18. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
19. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
20. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
